STAAR Surgical Co. 10-Q Summary: Quarter Ended March 28, 2025
Business Context and Reporting Period
STAAR Surgical Co. (STAA) designs, develops, and sells implantable Collamer lenses (ICLs) for refractive surgery. This report covers the quarterly period ended March 28, 2025. The Company is a large accelerated filer incorporated in Delaware. As of May 2, 2025, there were 49,526,129 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Sales | $42.6 million | $77.4 million |
| Gross Profit | $28.0 million | $61.0 million |
| Gross Margin | 65.8% | 78.9% |
| Operating Loss | $(57.4) million | $(2.3) million |
| Net Loss | $(54.2) million | $(3.3) million |
| Diluted EPS | $(1.10) | $(0.07) |
| Cash and Cash Equivalents | $173.1 million | $224.0 million |
| Investments Available for Sale | $49.6 million | $86.3 million |
| Working Capital | $258.1 million | $297.6 million |
| Operating Cash Flow | $(5.7) million | $21.7 million |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 45% year-over-year, driven primarily by a 99% drop in sales to China distributors ($0.4 million vs. $38.5 million). China distributors are utilizing existing inventory levels built up in anticipation of higher demand in late 2024.
- Restructuring Charges: The Company incurred $22.7 million in restructuring, impairment, and related charges, compared to none in the prior year. This includes $9.4 million in severance and consulting, $7.1 million in fixed asset impairment, $3.4 million in lease impairment, and $2.8 million in software impairment.
- Margin Compression: Gross margin declined to 65.8% from 78.9% due to lower production volumes increasing unit costs, higher inventory reserves, and period costs associated with expanding manufacturing in Switzerland.
- Geographic Shifts: While APAC sales dropped 61%, EMEA sales increased 10% and Americas sales increased 9%.
Outlook, Risks, and Management Commentary
- China Strategy: Management anticipates minimal China sales in the first half of 2025 as distributors deplete inventory. Sales are expected to normalize in the third quarter of 2025. To mitigate tariff risks, the Company implemented consignment agreements with Chinese distributors in April 2025 and is ramping up production in Switzerland.
- Leadership Realignment: The Company is undergoing a leadership team change and structural realignment to reduce costs and discretionary spending to return to sustainable growth.
- Liquidity: The Company maintains strong liquidity with $222.8 million in cash and investments. Management believes this is sufficient to meet needs for at least 12 months.
- Risks: Key risks include prolonged slowdowns in China, trade tariffs between the U.S. and China, and the success of the new leadership structure in restoring growth.
Investor Verification Checklist
- Verify the timeline for China distributor inventory depletion and the expected return to normalized sales in Q3 2025.
- Assess the impact of the $22.7 million restructuring charge on future operating expenses and the effectiveness of the cost-cutting measures.
- Monitor the execution of the consignment model in China and the ramp-up of Swiss manufacturing capacity to mitigate tariff exposure.
- Review the progress of the leadership realignment and its effect on operational efficiency and strategic direction.
- Track the Company's ability to maintain gross margins as production volumes fluctuate and new manufacturing capabilities come online.